SSTR2 and epilepsy: Of note, because the SST2 display both anti‐proliferative and anti‐epileptic properties [43], our MRgFUS noninvasive approach could also be of particular interest to test the therapeutic values of SST2 agonists in preclinical models of brain tumours and epilepsy.